Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Shares Shorted: Short Interest Down 93.8% in September

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS – Get Free Report) was the recipient of a significant drop in short interest in the month of September. As of September 30th, there was short interest totaling 5,591 shares, a drop of 93.8% from the September 15th total of 90,785 shares. Based on an average daily trading volume, of 21,117 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Get Cyclacel Pharmaceuticals alerts:

Read Our Latest Research Report on BGMS

Cyclacel Pharmaceuticals Trading Up 3.4%

Shares of NASDAQ:BGMS opened at $0.85 on Friday. The firm has a market cap of $4.69 million, a price-to-earnings ratio of -0.23 and a beta of -0.39. Cyclacel Pharmaceuticals has a 1 year low of $0.57 and a 1 year high of $6.70. The business has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $0.94.

Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $0.34 million during the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 31.60% and a negative net margin of 118.27%.

About Cyclacel Pharmaceuticals

(Get Free Report)

Cyclacel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted medicines for the treatment of cancer. Its research programs center on small-molecule therapies designed to interfere with key cell-cycle and transcription processes involved in tumor growth.

The company’s pipeline has included fadraciclib (CYC065), an oral cyclin-dependent kinase inhibitor being studied for advanced solid tumors and hematologic malignancies. Cyclacel has also developed sapacitabine (CYC682), an oral nucleoside analog, and seliciclib (CYC202), an earlier-stage cyclin-dependent kinase inhibitor.

Further Reading

• Five stocks we like better than Cyclacel Pharmaceuticals
• Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
• Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
• Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
• Arista Networks Plugs Into All-Time Highs

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.